USFDA grants EIR to Natco Pharma for Kothur facility

Indian pharmaceutical company, Natco Pharma Limited, announced that it has received an EIR for Kothur’s formulation facility (Telangana).

In a BSE filing made on April 25 (Saturday), the company informed that US Food & Drug Administration (USFDA) has given an establishment inspection report (EIR) for the successful closure of the inspection held at a drug formulation facility in Kothur village in the state of Telangana. The company added that the EIR has been given for the pre-approval inspection conducted at this facility from March 2 to 6, 2020.

Based in Hyderabad, Natco Pharma is R&D focussed pharmaceutical company, engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It is the market leader in branded oncology medicines in India as well as ranks among country’s top-three in producing Hepatitis C drugs.

At 10.10 am on Monday, the stock of Natco Pharma Ltd is trading at Rs 642.40, up by 2.89 per cent against its previous close of Rs 624.35. Its 52-week high is recorded at Rs 737.90 while, its 52-week low is Rs 450.00 on BSE.